Glofitamab induces high response rates in high-risk MCL: subgroup analysis from a Phase I/II study
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2024-12-08
Просмотров: 79
Описание:
Tycel Phillips, MD, City of Hope, Duarte, CA, comments on the results of a study evaluating glofitamab in patients with high-risk mantle cell lymphoma (MCL). Dr Phillips notes that, despite a small sample size, the study found no substantial difference in outcomes between patients with high-risk features and those without, suggesting that glofitamab may be effective in this patient population. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
